atezolizumab


( Last Updated : August 4, 2022)
Generic Name:
atezolizumab
Project Status:
Active
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Hoffmann-La Roche
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0269-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
​Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
"​Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs)."
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open 26-Jan-22
Call for patient/clinician input closed 18-Mar-22
Clarification:

- Patient input submission received from Lung Cancer Canada and Lung Health Foundation / The Ontario Lung Association

Submission received 24-Feb-22
Submission accepted 10-Mar-22
Review initiated 11-Mar-22
Draft CADTH review report(s) provided to sponsor for comment 26-May-22
Deadline for sponsors comments 06-Jun-22
CADTH review report(s) and responses to comments provided to sponsor 30-Jun-22
Expert committee meeting (initial) 13-Jul-22
Draft recommendation issued to sponsor 26-Jul-22
Draft recommendation posted for stakeholder feedback 04-Aug-22
End of feedback period 18-Aug-22